AcelRx Story

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;'>AP</div>
ACRX -- USA Stock  

USD 2.40  0.01  0.41%

The upcoming quarterly report is expected on the 15th of March 2021. The stock experiences an active upward rally. As many millenniums are getting excited about healthcare space, it is only fair to break down the feasibility of shorting AcelRx Pharmaceuticals. I will address why investors ignored this entity since the beginning of the current economic outlook.
Published over a week ago
View all stories for AcelRx Pharmaceuticals | View All Stories
Our current take on AcelRx (NASDAQ:ACRX) analyst consensus
AcelRx Pharmaceuticals is UNDERVALUED at 2.48 per share with modest projections ahead. We provide trade advice to complement the prevailing expert consensus on AcelRx Pharmaceuticals. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
What is the right price you would pay to acquire a share of AcelRx Pharmaceuticals? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.

What is happening with AcelRx Pharmaceuticals this year

Annual and quarterly reports issued by AcelRx Pharmaceuticals are formal financial statements that are published yearly and quarterly and sent to AcelRx stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934. Companies such as AcelRx Pharmaceuticals often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.

How AcelRx utilizes its cash?

To perform a cash flow analysis of AcelRx Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash AcelRx Pharmaceuticals is receiving and how much cash it distributes out in a given period. The AcelRx Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. AcelRx Pharmaceuticals Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. AcelRx Pharmaceuticals reported Net Cash Flow from Operations of (46.06 Million) in 2020

Acquisition by Richard Afable of 15000 shares of AcelRx Pharmaceuticals subject to Rule 16b-3

Legal trades by AcelRx Pharmaceuticals insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
AcelRx insider trading alert for grant of stock option (right to buy) by Richard Afable, the corporate stakeholder, on 16th of June 2020. This event was filed by Acelrx Pharmaceuticals In with SEC on 2020-06-16. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is AcelRx a risky opportunity?

Let's check the volatility. AcelRx is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind AcelRx (NASDAQ:ACRX) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. acquiring a share of an AcelRx Pharmaceuticals stock makes you a part-owner of that company.

AcelRx Pharmaceuticals Current Consensus

Here is the current trade recommendation based on an ongoing consensus estimate among financial analysis covering AcelRx Pharmaceuticals. The AcelRx consensus assessment is calculated by taking the average estimates from all of the analysts covering AcelRx Pharmaceuticals

Strong Buy
4
Strong Buy4100.0
Buy00.0
Hold00.0
Sell00.0
Strong Sell00.0

Our perspective of the current AcelRx Pharmaceuticals rise

Treynor ratio is down to 0.3. It may suggest a possible volatility slide. AcelRx Pharmaceuticals exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate AcelRx Pharmaceuticals individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about AcelRx Pharmaceuticals future systematic risk.

While some companies under the drug manufacturers?specialty & generic industry are still a bit expensive, AcelRx Pharmaceuticals may offer a potential longer-term growth to investors. To conclude, as of the 12th of January 2021, we see that AcelRx Pharmaceuticals slowly supersedes the market. The company is undervalued with quite high chance of bankruptcy within the next 24 months. However, our primary 30 days recommendation on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of AcelRx Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com